Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Piotr Rutkowski et al.|The Lancet Oncology|2021Cited by 389
Skin cancer classification via convolutional neural networks: systematic review of studies involving human expertsSarah Haggenmüller, Mildred Sergon, Roman C. Maron et al.|European Journal of Cancer|2021Cited by 246
Human Melanoma Progression in Skin ReconstructsFriedegund Meier, Meenhard Herlyn|American Journal Of Pathology|2000Cited by 236
Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Friedegund Meier|Cancer Medicine|2012Cited by 152
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Daniil Stroyakovskiy, Corneel Coens et al.|The Lancet Oncology|2021Cited by 72